Eμ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia

Iria Fernandez Botana, Susanne Gonder (Main author), Vanessa Klapp, Etienne Moussay*, Jerome Paggetti*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Despite being the most common adult leukemia in the western world, Chronic Lymphocytic Leukemia (CLL) remains a life-threatening and incurable disease. Efforts to develop new treatments are highly dependent on the availability of appropriate mouse models for pre-clinical testing. The Eμ-TCL1 mouse model is the most established pre-clinical approach to study CLL pathobiology and response to treatment, backed by numerous studies highlighting its resemblance to the most aggressive form of this malignancy. In contrast to the transgenic Eμ-TCL1 model, employing the adoptive transfer of Eμ-TCL1-derived splenocytes in immunocompetent C57BL/6 mice results in a comparably rapid (e.g., leukemic development within weeks compared to months in the transgenic model) and reliable model mimicking CLL. In this chapter, we would like to provide readers with a thoroughly optimized, detailed, and comprehensive protocol to use the adoptive transfer Eμ-TCL1 model in their research.

Original languageEnglish
JournalMethods in Cell Biology
DOIs
Publication statusAccepted/In press - 18 Apr 2024

Keywords

  • Chemotherapy
  • CLL pathogenesis
  • Immunotherapy
  • Splenomegaly

Fingerprint

Dive into the research topics of 'Eμ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this